GlaxoSmithKline: FDA recommends removing warning statements on NRT products The U.S. FDA announced a recommendation to remove certain warning statements and modifications of the instructions for use of nicotine replacement therapy products. As leaders in smoking cessation, GlaxoSmithKline Consumer Healthcare commends the FDA on this action and believes this is a positive step to help more smokers quit and will work with the FDA to implement these changes to our product labeling as soon as possible. The changes help eliminate barriers for smokers and include updates to the warnings and directions sections in the current label.
News For GSK From The Last 14 Days
Check below for free stories on GSK the last two weeks.
Ligand says partner GSK submits application for Promacta Ligand Pharmaceuticals (LGND) said its partner GlaxoSmithKline (GSK) announced today the submission of a supplemental New Drug Application to the FDA for Promacta for the treatment of cytopenias in patients with severe aplastic anaemia who have had an insufficient response to immunosuppressive therapy.